AMGEN and Janssen Biotech Inc. announced a collaboration to evaluate the combination of Amgen’s Kyprolis (carfilzomib) and Janssen’s Darzalex (daratumumab) in multiple clinical studies in patients with multiple myeloma. Under the agreement, the companies may elect to supply drug only or supply drug and share development costs on a study-by-study basis.The first study initiated as...
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe